Report Overview
The treatment-resistant depression treatment market is set to reach USD 5.34 billion in 2031, growing at a CAGR of 5.9% from USD 4.02 billion in 2026.
The treatment-resistant depression treatment market is growing significantly, owing to the escalating worldwide major depressive disorder cases and the increasing number of patients not responding to standard antidepressant treatments. The demand for the market is attributable to increased mental health awareness, enhanced diagnosis rates, rising healthcare expenditure, and the quick advancement of inventive therapies like ketamine-based therapies, psychedelic-assisted treatments, neuromodulation devices, and next-generation antidepressants. America dominates the market owing to its advanced psychiatric healthcare infrastructure, high prevalence of depression, and strong presence of leading market players, while Asia-Pacific is expected to witness the fastest growth due to improving mental healthcare access, rising awareness, and increasing investments in psychiatric treatment services.
Pharmaceutical companies are investing a lot of money into research and development of totally new types of drugs that work in ways different from the traditional monoamine-based ones.
These include drugs that modulate the glutamate system and also enhance neuroplasticity.
Alto Neuroscience, Inc., after a successful outcome from a recent FDA meeting, the company plans to accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD).
The $50 million private placement is supposed to be spent on the expanded development of ALTO-207.
The Company expects to start a Phase 3 study by early 2027 after Phase 3 readiness work and aligning with the FDA on the planned study design.
In March 2026, AtaiBeckley Inc. made public a successful End-of-Phase 2 meeting with the FDA concerning the development of BPL-003 for treatment-resistant depression (TRD)
Besides, the market expansion is being further driven by the rising use of intranasal esketamine therapies, transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), and digital mental health solutions.
SPRAVATO® (esketamine) is approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression.
Governments all over the globe are raising their mental health care budgets as a response to the growing number of people with treatment-resistant depression (TRD).
Initiatives like the U.S. National Institute of Mental Health, the UK National Health Service's "Improving Access to Psychological Therapies (IAPT)", and India's National Mental Health Programme are facilitating depression recognition, timely diagnosis, and provision of psychiatric treatments, thus helping the market to grow.
However, the market still experiences several difficulties, such as the high costs of treatment, the social stigma related to mental disorders, the scarce availability of specialized psychiatric services in developing areas, and the issues of long-term safety and effectiveness of new drugs.
North America leads the market, while Asia-Pacific is expected to witness the fastest growth due to improving mental healthcare infrastructure and awareness.
NMDA receptor antagonists are expected to be the fastest-growing segment due to their rapid antidepressant effects and increasing adoption of ketamine-based therapies for treatment-resistant depression.
Parenteral administration is anticipated to witness the fastest growth owing to the rising use of injectable and intranasal therapies in clinical settings.
In 2025, Online pharmacies were the major segment by distribution channel, accounting for X% share by value, followed by hospital pharmacies accounting for X% share in the same year.
Online pharmacies are projected to grow rapidly due to increasing digital healthcare adoption and convenient access to mental health medications.
Specialty clinics are expected to be the fastest-growing segment because of rising demand for specialized psychiatric care and advanced TRD treatment services.
Market Dynamics
Drivers
Rising Prevalence of Depression and Mental Health Disorders
The increasing occurrence of depression and other mental health issues is one of the main reasons for the expansion of the Treatment-Resistant Depression (TRD) treatment sector. Stress, anxiety, social isolation, financial problems, work pressure, and lifestyle-related difficulties are the factors that have largely led to a rise in the global population of those affected by major depressive disorder. Depression has been identified by worldwide health organizations as one of the top causes of disability and impaired quality of life, impacting individuals regardless of their ages.
The latest research directed by scholars of Johns Hopkins Bloomberg School of Public Health Department of Health Policy and Management revealed the incidence of self-reported mental health crises nationwide, with the existence of extreme disparities by age, race, and socio-economic status and conditions.
In the latest research, over 1, 900 adult Americans were surveyed to find out if they had a mental health crisis in the last year.
This study discovered that young people aged 18 to 29 were the most burdened with crisis at 15.1%, while only 2.6% of those over 60 reported experiencing a crisis.
Black (11.8%) and Hispanic (10.5%) adults reported significantly higher figures than white adults (7.4%).
A significant number of people suffering from depression do not get a satisfactory response to the usual antidepressant medicines.
This results in more cases of depression that do not respond to the treatment, and hence the need for more advanced therapies.
Rising Suicidal Cases
Depression may cause suicide, raising the concern for advanced depression treatment methods. According to the WHO, around 7 million people die from suicide each year, and it is the fourth-leading cause of death in people aged between 15 and 29 years. The Virginia Tech School of Education states that depression and suicide are correlated, and the people suffering from depression during the winter months don’t abate going into the spring months. Moreover, one death per eleven minutes happened from suicide in the US in 2021, totaling 48,183 deaths. The growing number of suicide cases and their relation with depression are expected to bolster the treatment-resistant depression treatment market.
Novel Treatment Developments
The treatment-resistant depression treatment market key players are advancing the treatment methods through expert research and clinical trial. Currently, augmentation strategies of second-generation antipsychotics and lithium seed are the strongest medications for TRDs. S-Ketamine is a novel treatment approved specifically for TRDs, and various studies show the rapid, sustained effect on mental health. In September 2021, XWPharma Ltd. announced doses of its XW10508 in a human study. Moreover, the approval of treatment-resistant depression treatments by the US FDA in the region is further anticipated to widen the treatment-resistant depression treatment market size.
Key Developments
January 2026: The 2026 American College of Neuropsychopharmacology (ACNP) Annual Meeting featured 11 new neuropsychiatry abstracts from Johnson & Johnson, which demonstrated its leadership in depression therapeutics through new Phase 3 SPRAVATO analyses and CAPLYTA studies and seltorexant research into major depressive disorder and treatment-resistant depression.
Market Segmentation
By Drug Type: Antidepressants
By Drug type, the treatment-depression resistance treatment market is segmented into NMDA receptor antagonists, antidepressants, antipsychotics, and others. Antidepressants are set to grow at a steady rate, fueled by growing suicidal & depression prevalence.
Ongoing novel treatment development has outlined the market scope for TRD treatment. The antidepressants segment is expected to show considerable growth, fueled by the growing demand for faster-acting drugs for TRD.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 4.02 billion |
| Total Market Size in 2031 | USD 5.34 billion |
| Forecast Unit | USD Billion |
| Growth Rate | 5.9% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Drug Type, Route of Administration, Distribution Channel, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
High global prevalence rate, with nearly 1 billion people suffering from mental disorders, including depression, has bolstered the demand for effective fast-responsive antidepressants.
Major depressive disorder (MDD), having a huge economic toll, has further escalated the consumer shift from traditional treatments towards NMDA modulations, further fueling the overall market
Ongoing development of new antidepressants with global pharma companies like Lupin, establishing a license and supply agreement to commercialize their antidepressant “DeslaFlex”, will improve the market scope in countries like Canada.
Launching of campaigns such as “Generation Fine” launched by international conglomerates like Johnson & Johnson is further set to positively impact oral antidepressant demand.
The growing mental health burden has expanded the novel therapy options beyond standard monoamine-based antidepressants, thereby encouraging broader usage of advanced regimens.
Regional Analysis
North America: the US
Demand Drivers
Ongoing development of novel therapies and antipsychotics, such as Johnson & Johnson’s recently FDA-approved “Caplyta” as an adjunctive therapy for MDD, has transformed the overall market landscape in regional economies like the USA.
The growing social & economic burden of TRD has incentivized investments in better treatments with improved access in North America.
Development of novel therapeutic approaches to treat depression symptoms has led to new treatment developments for TRD in NA economies. For instance, in December 2025, Health Canada authorized Biogen Canada Inc’s “ZURZUVAE” for treating severe to moderate PDD in adults.
Regulatory Overview
Regulatory standards and documents issued by concerned authorities, such as the Food and Drug Administration (FDA), outline guidance for clinical development of monotherapeutic and adjunctive treatment drugs for MDD disorder.
Filing Clinical Trial Applications (CTA) under Part C, Division 5 of the Food & Drug Regulation of Canada governs clinical trials of drugs in humans. New Drug Submission (NDS) and Abbreviated New Drug Submission (ANDSs) guidance issued by Health Canada outlines clinical compliance.
Epidemiology
The AMI (Any Mental Illness) prevalence has remained steady in the United States, with nearly 23.4% adults experiencing AMI, which is set to expand the market outlook for TRD treatment drugs.
MDD has become one of the leading causes of disability for Americans aged 15 to 44 years, with nearly 21% of adults developing MDD at some point in their lives.
The prevalence rate reaching nearly 19.1% for anxiety disorders and 15.5% for major depressive disorder, according to the National Alliance on Mental Illness, has incentivized efforts for a new therapeutic approach in the USA
Global players like Johnson & Johnson are commercializing their antipsychotics, namely “CAPLYTA”, in the USA, which can be used with antidepressants for MDD treatment in adults. Such developments offer new market potential.
Regulatory Framework
The FDA has issued guidance documents to regulate drug development for treating mental illnesses like major depressive disorder (MDD).
For TRD trials, the FDA governs the enrollment of patients not responding to more than one dose of antidepressants, with studies conducted to understand the root cause.
List of Companies
Johnson & Johnson
Axsome Therapeutics
AtaiBeckley Inc.
AbbVie Inc.
Compass Pathways
Tasman Therapeutics
NRx Pharmaceuticals
Eli Lilly and Company
GH Research
Relmada Therapeutics
Pfizer Inc
Supernus Pharmaceuticals, Inc
Johnson & Johnson operates as an international healthcare and pharmaceutical firm that specializes in neuroscience, oncology, immunology, and medical technology fields. Johnson & Johnson Innovative Medicine serves as the company's pharmaceutical division, which establishes the company as a central nervous system (CNS) disorder innovator that develops new depression treatments. The company focuses on creating new psychiatric treatments that operate through specific biological mechanisms because they need to address psychiatric conditions that current antidepressant medications cannot resolve.
Johnson & Johnson maintains a dominant market share in treatment-resistant depression therapy through its successful product Spravato (esketamine). The product became the first FDA-approved ketamine-derived therapy for adults with treatment-resistant depression and significantly changed the clinical treatment approach for severe depression cases. The company has developed a competitive advantage in the fast-expanding treatment-resistant depression therapeutics sector through its extensive marketing network and its partnerships with psychiatric treatment facilities and ongoing product label enhancements.
Treatment-Resistant Depression Treatment Market Scope:
Market Segmentation
By Geography
Key Countries Analysis
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Key Market Findings and Highlights
1.2. Market Size and Forecast Snapshot (2021–2031)
1.3. Competitive Landscape Overview
1.4. Strategic Recommendations
2. DISEASE & EPIDEMIOLOGY ANALYSIS
2.1. Definition and Pathophysiology of Treatment-Resistant Depression
2.2. Diagnostic Criteria and Staging Models
2.3. Global and Regional Prevalence
2.4. Epidemiology by Subtype, Severity, and Demographics
2.5. Comorbidities and Risk Factors
2.6. Disease Burden and Unmet Medical Needs
3. MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends and Emerging Themes
3.5. Porter’s Five Forces Analysis
3.6. Impact of Macroeconomic and Industry Factors
4. COMMERCIAL & MARKET ACCESS
4.1. Pricing and Reimbursement Landscape
4.2. Market Access Strategies and HTA Considerations
4.3. Patient Journey and Treatment Algorithms
4.4. Payer Perspectives and Value-Based Contracting
5. INNOVATION & PIPELINE LANDSCAPE
5.1. Overview of Pipeline by Phase and Modality
5.2. Key Pipeline Candidates (Mechanism of Action, Trial Status)
5.3. Novel Mechanisms (e.g., NMDA antagonists, psychedelics, others)
5.4. Clinical Trial Design Considerations and Endpoints
5.5. Regulatory and Development Risks
6. TREATMENT LANDSCAPE
6.1. Current Standard of Care and Treatment Guidelines
6.2. Pharmacotherapy Options (Approved and Off-Label)
6.3. Neuromodulation and Non-Pharmacological Interventions
6.4. Combination Therapies and Sequencing Strategies
6.5. Real-World Treatment Patterns and Adherence
7. TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET SIZE & FORECAST
7.1. Global Market Size and Forecast
7.2. Drugs and Sales Forecast
7.2.1. Esketamine
7.2.2. AXS-05
7.2.3. Brexpiprazole
7.2.4. Psilocybin
7.2.5. Aripiprazole
7.2.6. Zuranolone
7.2.7. Other Approved Augmentation Drugs
7.3. Sensitivity Analysis and Key Influencers
8. TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET SEGMENTATION
8.1. By Drug Type
8.1.1. Introduction
8.1.2. NMDA Receptor Antagonists
8.1.3. Antidepressants
8.1.4. Antipsychotics
8.1.5. Others
8.2. By Route of Administration
8.2.1. Introduction
8.2.2. Oral
8.2.3. Parental
8.2.4. Others
8.3. By Distribution Channel
8.3.1. Introduction
8.3.2. Hospital Pharmacies
8.3.3. Drug Stores & Retail Pharmacies
8.3.4. Online Pharmacies
8.4. By End User
8.4.1. Introduction
8.4.2. Hospitals
8.4.3. Specialty Clinics
8.4.4. Others
9. TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET GEOGRAPHICAL ANALYSIS (REGIONAL LEVEL)
9.1. Introduction
9.2. North America
9.2.1. Market Size & Growth
9.2.2. Demand Drivers
9.2.3. Regulatory Overview (Regional Level)
9.2.4. Competitive Intensity
9.3. Europe
9.3.1. Market Size & Growth
9.3.2. Demand Drivers
9.3.3. Regulatory Overview (Regional Level)
9.3.4. Competitive Intensity
9.4. Asia-Pacific
9.4.1. Market Size & Growth
9.4.2. Demand Drivers
9.4.3. Regulatory Overview (Regional Level)
9.4.4. Competitive Intensity
9.5. South America
9.5.1. Market Size & Growth
9.5.2. Demand Drivers
9.5.3. Regulatory Overview (Regional Level)
9.5.4. Competitive Intensity
9.6. Middle East & Africa
9.6.1. Market Size & Growth
9.6.2. Demand Drivers
9.6.3. Regulatory Overview (Regional Level)
9.6.4. Competitive Intensity
10. KEY COUNTRIES ANALYSIS
10.1. United States
10.1.1. Market Size and Forecast
10.1.2. Epidemiology
10.1.3. Regulatory Framework
10.1.4. Reimbursement
10.1.5. Key Companies and Products Presence
10.2. Canada
10.2.1. Market Size and Forecast
10.2.2. Epidemiology
10.2.3. Regulatory Framework
10.2.4. Reimbursement
10.2.5. Key Companies and Products Presence
10.3. Germany
10.3.1. Market Size and Forecast
10.3.2. Epidemiology
10.3.3. Regulatory Framework
10.3.4. Reimbursement
10.3.5. Key Companies and Products Presence
10.4. United Kingdom
10.4.1. Market Size and Forecast
10.4.2. Epidemiology
10.4.3. Regulatory Framework
10.4.4. Reimbursement
10.4.5. Key Companies and Products Presence
10.5. France
10.5.1. Market Size and Forecast
10.5.2. Epidemiology
10.5.3. Regulatory Framework
10.5.4. Reimbursement
10.5.5. Key Companies and Products Presence
10.6. Italy
10.6.1. Market Size and Forecast
10.6.2. Epidemiology
10.6.3. Regulatory Framework
10.6.4. Reimbursement
10.6.5. Key Companies and Products Presence
10.7. Spain
10.7.1. Market Size and Forecast
10.7.2. Epidemiology
10.7.3. Regulatory Framework
10.7.4. Reimbursement
10.7.5. Key Companies and Products Presence
10.8. China
10.8.1. Market Size and Forecast
10.8.2. Epidemiology
10.8.3. Regulatory Framework
10.8.4. Reimbursement
10.8.5. Key Companies and Products Presence
10.9. Japan
10.9.1. Market Size and Forecast
10.9.2. Epidemiology
10.9.3. Regulatory Framework
10.9.4. Reimbursement
10.9.5. Key Companies and Products Presence
10.10. India
10.10.1. Market Size and Forecast
10.10.2. Epidemiology
10.10.3. Regulatory Framework
10.10.4. Reimbursement
10.10.5. Key Companies and Products Presence
10.11. South Korea
10.11.1. Market Size and Forecast
10.11.2. Epidemiology
10.11.3. Regulatory Framework
10.11.4. Reimbursement
10.11.5. Key Companies and Products Presence
10.12. Brazil
10.12.1. Market Size and Forecast
10.12.2. Epidemiology
10.12.3. Regulatory Framework
10.12.4. Reimbursement
10.12.5. Key Companies and Products Presence
11. REGULATORY & POLICY LANDSCAPE
12. COMPETITIVE ENVIRONMENT
12.1. Market Share Analysis
12.2. Competitive Benchmarking
12.3. Strategic Initiatives (M&A, Partnerships, Licensing)
12.4. SWOT Analysis of Key Players
13. COMPANY PROFILES
13.1. Johnson & Johnson
13.2. Axsome Therapeutics
13.3. AtaiBeckley Inc.
13.4. AbbVie Inc.
13.5. Compass Pathways
13.6. Tasman Therapeutics
13.7. NRx Pharmaceuticals
13.8. Eli Lilly and Company
13.9. GH Research
13.10. Relmada Therapeutics
13.11. Pfizer Inc
13.12. Supernus Pharmaceuticals, Inc
14. FUTURE OUTLOOK
14.1. Market Evolution Scenarios (Base, Optimistic, Pessimistic)
14.2. Disruptive Technologies and Innovations
14.3. Long-Term Growth Drivers and Challenges
14.4. Strategic Imperatives for Stakeholders
15. METHODOLOGY
15.1. Research Design and Approach
15.2. Data Sources and Validation
15.3. Market Size Estimation and Forecasting Methodology
15.4. Assumptions and Limitations
15.5. Abbreviations and Glossary
Treatment-Resistant Depression Treatment Market Report
Trusted by the world's leading organizations
